US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
MapLight Therapeutics, Inc. - Common Stock
(NQ:
MPLT
)
8.830
-0.320 (-3.50%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MapLight Therapeutics, Inc. - Common Stock
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
October 06, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics to Participate in Upcoming Investor Conference
September 09, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Announces $150 Million Private Placement Financing
August 13, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
July 27, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
July 27, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Announces Changes to Board of Directors
June 24, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
June 22, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics to Participate in Upcoming Investor Conferences
May 08, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 01, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 26, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics to Participate in Upcoming Investor Conferences
March 02, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
January 09, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
January 05, 2026
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
December 16, 2025
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
December 04, 2025
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 29, 2025
From
MapLight Therapeutics, Inc.
Via
GlobeNewswire
